The Center for Addiction Medicine (CAM) is one of the major clinical research programs of the Department of Psychiatry at Massachusetts General Hospital. CAM provides treatment, research and training opportunities in a multidisciplinary, outpatient setting. Medicine alcoholism.
The Recovery Research Institute (RRI) is a non-profit research institute of Mass General's Department of Psychiatry and Harvard Medical School (501(c)(3)) located in Boston. In recognition of the increased public health and broader societal harms related to substance use disorders and the lack of emphasis on research pertaining to how individuals achieve remission and sustain long-term recovery, the Recovery Research institute was created under the direction of John F. Kelly, PhD in 2012 with a goal to enhance the public health impact of addiction recovery science through the summary, synthesis, and dissemination of scientific findings and the conduct of novel research investigation.
CAM is involved in various collaborative efforts with clinics within Massachusetts General Hospital, Harvard Medical School, MIT and Tufts University, as well as community agencies in the Boston area.
Evins, MD, MPH
CAM Founding Director, Cox Family Associate Professor of Psychiatry in the Field of Addiction Medicine, Harvard Medical School
Dr. Evins completed her residency in adult psychiatry at the Massachusetts Mental Health Center and Longwood Psychiatry Residency Training Program and fellowships in molecular biology at the Mailman Research Center of McLean Hospital and in clinical research at the Schizophrenia program at MGH. She completed a Masters in Public Health with a concentration in Clinical Effectiveness at the Harvard School of Public Health in 2005. She has been an active member of the MGH Schizophrenia and Depression Clinical and Research Program since 1995. She founded the CAM in 2005.
Dr. Evins' research interests include pharmacotherapy for nicotine dependence, co-occurring psychiatric and substance use disorders, negative symptoms and cognitive dysfunction in schizophrenia, and impact of cannabis on cognition and psychiatric illness. Dr Evins has authored articles, book chapters, and reviews concerning topics in this field.
Dr. Evins has twice been the recipient of the National Alliance for Research on Schizophrenia and Affective Disorders Young Investigator Award, and has been awarded the New Clinical Drug Evaluation Unit Award for Young Investigators sponsored by the National Institute of Mental Health, the Massachusetts Department of Public Health Young Investigator Award and three career development awards from NIDA. She is currently supported by six major grants from NIDA, NIMH, and NHLBI to test novel therapies for nicotine dependence in the general population and in those with co-occurring psychiatric disorders.
CAM Associate Director, Program Director of the Addiction Recovery Management Service, Principal Investigator, Associate Professor, Harvard Medical School
Dr. Kelly is the Elizabeth R. Spallin Associate Professor of Psychiatry in Addiction Medicine at Harvard Medical School, as well as the founder and Director of the Recovery Research Institute at MGH. The American Psychological Association (APA) Society of Addiction Psychology, and is also a Fellow of APA. He has served as a consultant to U.S. federal agencies such as the White House Office of National Drug Control Policy, the Substance Abuse and Mental Health Services Administration, and the national Institutes of Health, to non-Federal institutions, such as the Betty Ford Institute and the Hazelden Foundation, and internationally to foreign governments.
He is currently an Associate Editor for the journals, Addiction and the Journal of Substance Abuse Treatment. He has more than 100 publications in the field of addiction. His clinical and research work has focused on addiction treatment and the recovery process, which has included specific research on the effectiveness of mutual-help groups, such as Alcoholics Anonymous, as adjuncts to formal care. His research has also focused on the translation and implementation of evidence-based practice, addiction and criminal justice, addiction treatment theories and mechanisms of action, and reducing stigma associated with addiction.
Gladys Pachas, MD
CAM Program Director, Assistant in Research Psychiatry MGH, Instructor in Psychiatry Harvard Medical School
Dr. Pachas received her medical degree from the San Martin de Porres University and her health services management and public health training from the National University Mayor de San Marcos in Lima, Peru. Her research interests are the development of evidence-based novel treatment for smoking cessation and relapse prevention in people with and without serious mental illness. Dr. Pachas is the recipient of the NIMH-NCDEU Young Investigator Award, the MGH Clinical Research Day Departmental Award in Psychiatry, the NIH-NIDA Interdisciplinary Research Training Institute on Hispanic Drug Abuse Fellowship, the American Society of Clinical Psychopharmacology Fellowship and the Society for Research on Nicotine and Tobacco Health Disparities fellowship. Dr. Pachas is involved in the clinical component of complex Phase II trials of novel pharmacologic agents for smoking cessation and relapse prevention.
Director of Dual Diagnoses Studies at the Depression Clinical Research Program, Principal Investigator, Assistant Professor in Psychology, Harvard Medical School
Dr. Pedrelli is a clinical psychologist with expertise in comorbid disorders. She received her PhD in Clinical Psychology from the Joint Doctoral Program at University of California San Diego and San Diego State University and completed her post-doctoral work at MGH. Her program of research focuses on explicating the etiology of co-occurring mood disorders and alcohol use disorders and on developing psychosocial treatments for these conditions. She has been awarded funding from Harvard Medical School, the National Institute Of Alcohol Abuse and Alcoholism, and the ABMRF/The Foundation for Alcohol Research. Her current work includes a study examining the effectiveness of a novel psychosocial intervention for heavy drinking and depressive symptoms in college students, and a multi-method study investigating positive and negative reinforcement processes at the bases of binge drinking. She has published and presented extensively on the co-occurrence of depressive symptoms and substances use among college students. She is an expert in the delivery of CBT and developed several CBT based treatment manuals for patients with co-occurring disorders.
Bettina Hoeppner, PhD
Director of Biostatistics, Assistant Professor in Psychiatry, Harvard Medical School
Dr. Hoeppner is a health psychologist with expertise in longitudinal methodology, which she uses to explicate the mechanisms underlying behavioral change. She completed graduate training at the University of Rhode Island, earning a Masters in Psychology, a Masters in Statistics, and a PhD in psychology. She has collaborated on numerous health behavior change projects, using computer-delivered expert systems to provide participants with tailored intervention materials. She completed a postdoctoral fellowship at the Center of Alcohol and Addiction Studies at Brown University that focused on alcohol and tobacco use in adolescents and young adults.
Dr. Hoeppner joined the Center for Addiction Medicine in 2010. Her K01 research project used Ecological Momentary Assessment to delineate the temporal ordering of changes in smoking outcome expectancies relative to smoking cessation by collecting fine-grained, real-time data from college student smokers undergoing smoking cessation treatment. She plans to continue to use her advanced statistical training and experience with theory-driven health behavior interventions to take advantage of modern technology to delineate the causal mechanisms underlying the process of smoking cessation.
Medicine after drinking wine
Jodi Gilman, PhD
Director of Neuroscience for CAM, Neuroscientist, Principal Investigator, Assistant Professor in Psychiatry, Harvard Medical School
Dr. Gilman received her BS from Tufts University and her PhD in Neuroscience from Brown University, where she used neuroimaging techniques to study the acute and long-term functional and structural effects of alcohol on brain regions involved in motivation and emotion. She came to CAM in January 2013 to study the effects of cannabis in adolescents and young adults. She is the recipient of the Norman Zinberg Fellowship in Addiction Psychiatry from Harvard Medical School, as well as a Career Development Award from the National Institute on Drug Abuse entitled &ldquo,Neurobehavioral Characterization of Social Influence in Drug Addiction.&rdquo, Dr. Gilman&rsquo,s work has been featured in media outlets throughout the world, including Reuter&rsquo,s, NPR&rsquo,s Science Friday broadcast, and the BBC.
Director Psychology Services at CAM &, the MGH Schizophrenia Program, Co-Founder MGH First Episode and Early Psychosis Program, Assistant in Psychiatry MGH, Assistant Professor of Psychology, Harvard Medical School
Dr. Cather earned her undergraduate degree in biopsychology at Hamilton College and her doctorate in clinical psychology from Rutgers University, where she received specialized training in cognitive behavioral therapy (CBT) and behavioral medicine. She completed an internship at the University of Medicine and Dentistry of New Jersey (formerly Rutgers) and joined the Schizophrenia Clinical and Research Program in 1999 as a fellow. She has extensive experience as a clinician-researcher with first episode/early psychosis as well as with chronic schizophrenia and she has developed an international reputation as one of the few practitioners in the US skilled in CBT in schizophrenia.
Dr. Cather has worked with Dr. Evins since 1999 to investigate the efficacy of combined behavioral and pharmacological treatments for nicotine dependence in smokers with severe mental illness. She has manualized treatments for enhancing motivation to quit smoking, smoking cessation and relapse prevention for this population of smokers.
Melissa Maravic, PhD, MPH
Project Director, &ldquo,Integrated Smoking Cessation Treatment for Smokers with Serious Mental Illness&rdquo,
Dr Maravic received her BA from the University of Minnesota, Twin Cities and her MPH with a concentration in epidemiology and biostatistics from the Boston University School of Public Health. She joined CAM as a research fellow in 2005, where she focused on identifying predictors of smoking cessation among those with schizophrenia. She received her PhD in Medical Anthropology and Social Science Research Methods from the University Professors Program at Boston University. Her research interests are understanding and improving the health and mental health of vulnerable populations, with a specific focus on addiction, trauma and psychotic disorders. After spending several years as director of research and evaluation at a Latino community health center and as director of analytics and behavioral science at a health engagement management company, she has returned to CAM as Project Director of the Patient‑Centered Outcomes Research Institute (PCORI) project &ldquo,Integrated Smoking Cessation Treatment for Smokers with Serious Mental Illness&rdquo,.
Brandon G. Bergman, PhD
Dr. Bergman is a research scientist in the Recovery Research Institute within CAM, and a licensed staff psychologist in the hospital's Addiction Recovery Management Service, where he treats adolescents and young adults with substance use disorders (SUD). He also serves nationally as the secretary for Division 50 of the American Psychological Association (Addiction Psychology). Dr. Bergman&rsquo,s research interests include treatment/recovery among young adults with co-occurring SUD and psychiatric disorders as well as community-based mutual-help organizations. His work has been recognized by the National Institute on Drug Abuse, the Research Society on Alcoholism, and by an MGH/HMS institutional award. Dr. Bergman received his PhD in clinical psychology from Nova Southeastern University in Fort Lauderdale, FL, including a pre-doctoral clinical internship in the MGH/HMS Department of Psychiatry. He completed a combined clinical/research postdoctoral fellowship at ARMS and CAM in 2014.
Randi Schuster, PhD
Dr. Schuster received her BA from University of Maryland, College Park and her PhD in Clinical Psychology from University of Illinois at Chicago. In graduate school, she was funded by a NIDA National Research Service Award to study the cognitive effects of cannabis and tobacco use among at-risk young adults using ecological momentary assessment. She joined CAM in July 2014 as a post-doctoral fellow after completing her clinical internship in neuropsychology at MGH/Harvard Medical School. She is the recipient of the Norman Zinberg Fellowship in Addiction Psychiatry and the Livingston Fellowship from Harvard Medical School as well as the Louis V. Gerstner III Research Scholar Award from MGH. She is currently conducting research based out of Boston-area high schools on the utility of contingency management interventions in promoting cannabis abstinence as well as the reversibility of cognitive deficits during 30 days of cannabis discontinuation.
Hasan Onur Keles, PhD
Dr. Keles is conducting research using multi-modal imaging to detect the effects of acute intoxication on brain function. He received his PhD in Biomedical Engineering from University of Houston. He has received training in optical neuroimaging, electrophysiology, and nano- and micro-scale technologies. His aim is to apply his background in engineering to biology and medicine. Currently, Dr. Keles focuses on the neuroimaging techniques to understand the acute and long-term effects of cannabis on the brain.
Corrie L. Vilsaint, PhD
Dr. Vilsaint is a community psychologist who received her BA from the University of North Carolina at Chapel Hill and her PhD in psychology from the University of Virginia. In graduate school, she was funded by a National Research Service Award (F31) from the National Institute on Drug Abuse to study racial and ethnic disparities as outcomes of drug use. She also uses Item Response Theory to evaluate tests and measurements.
David Eddie, PhD
Dr. David Eddie received his BA from Columbia University and PhD in clinical psychology from Rutgers University. He completed his clinical internship at Massachusetts General Hospital, Harvard Medical School. While at Rutgers, he investigated neurobiological vulnerabilities that heighten risk for the development of dependence on alcohol and other drugs, as well as processes that maintain addictive disorders. He continues this research at Massachusetts General Hospital&rsquo,s Center for Addiction Medicine and Recovery Research Institute, where he is presently investigating psychophysiological biomarkers of alcohol use disorder relapse risk. He is also interested in addiction treatment and recovery processes, as well as drug and treatment policy, and is membership, and conference program chair for the American Psychological Association&rsquo,s Society of Addiction Psychology.
Haiyue Zhang, BA
Biostatistician, MGH Center for Addiction Medicine and MGH Biostatistics Center
Haiyue Zhang received her BA in science with a concentration in bioinformatics from Stony Brook University and completed the Master&rsquo,s Biostatistics program at the Harvard T.H. Chan School of Public Health. Her thesis was entitled &ldquo,Variable Selection Under Multiple Imputation For Missing Data". Her expertise includes data management, statistical modeling, survival analysis, and longitudinal analysis. Haiyu applies her background in biology and applied mathematics to her research and has research experience in the regulation of gene expression during Drosophila early development.
Julie Cristello, BA
Senior Clinical Research Coordinator
Julie Cristello graduated from Saint Anselm College where she majored in psychology. She currently works on three studies funded by the National Institute of Health designed to examine addiction treatment and mechanisms of behavior change. Her research interests include early intervention and substance use treatment for at-risk youth.
Nilo Fallah-Sohy, BA
Nilo Fallah-Sohy graduated from the University of Maryland, where she majored in psychology. She currently coordinates a study which aims to characterize and evaluate Recovery Commuinity Centers in New England and New York. Her research interests include screening and prevention in schools, as well as substance use and co-occuring disorders.
Nate Kelly, BA
Nate Kelly graduated from the University of Massachusetts Boston where he completed a double major in psychology and sociology. He currently works as a coordinator for two studies, as well as the Recovery Research Institute. Apart from substance use treatment, Nate&rsquo,s other research interests are communication and forensic psychology.
Jessica Powers, BA
Jessica Powers graduated with her BA in Psychology and Sociology from Northwestern University. While at CAM, she has been a Clinical Research Coordinator on the Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence. Her research interests include the commorbidity of substance use and mental illness, along with the influence of affect, specifically anhedonia, on smoking cessation.
Milena Radoman, BA
Research Coordinator, Programmer
Milena Radoman, who was born and raised in Montenegro, graduated from Wellesley College, where she majored in Neuroscience. At CAM she works primarily with Dr. Gilman on the acquisition of neurocognitive data, fMRI, and fNIRS analysis. Additionally, she designs and programs computer tasks needed for the studies and helps run analytical software used at CAM. Her research interests include understanding the neuroscience underlying nicotine addiction as well as decision-making and social influence in people who smoke marijuana and suffer from major depressive disorder. She is a language enthusiast and enjoys wilderness activities.
Nour Azzouz, BA
Nour Azzouz graduated from Wellesley College, where she majored in Neuroscience. Currently, she is involved in three NIH funded clinical studies, including the Nicotine Reduction in Cigarette Smokers trial, the Decision-Making and Drug Use trial and the Neural mechanisms of Food-Related Emotion Regulation trial. Her general areas of study include adolescent psychiatry, developmental neuroscience, and the neural correlates of decision making, emotion regulation, and addiction. She is primarily interested in investigating the neurobiological effects of childhood trauma on brain development.
Madeleine Fontaine, BA
Madeleine Fontaine graduated with her BA in Psychology from Clark University. At CAM she is working primarily on the Patient-Centered Outcomes Research Institute funded study investigating integrated smoking cessation treatment for smokers with serious mental illness. Her research interests include the intersection of race, class, and gender on addiction and substance use.
Alexandra Plante, MA
Alexandra Plante is the Marketing Communications Coordinator of the Recovery Research Institute. She manages written and visual content across social media accounts, the website, the Recovery Research Review monthly newsletter, and coordinates all media inquiries to the institute. Alexandra received her BA in Communication at the University of Massachusetts, Amherst and her MA in Quantitative Research in Communication from the University at Buffalo. In addition to substance use treatment and recovery, her research interests include studies of human behavior and decision-making.
Ufuoma Akpotaire, LLM
Ufuoma holds a Master&rsquo,s degree in law from the Columbia University School of Law, and currently serves as the CAM Grant Administrator. Ufuoma has worked in Grants Administration and Development for over five years and has experience managing government and foundation grants, contracts and subcontracts. Prior to joining the CAM team, Ufuoma worked closely with Program and Development Staff in non-profit organizations in New York and Florida. As the Grant Administrator, Ufuoma tracks and manages all funds for the CAM, works with Principal Investigators to submit grants to the NIH and serves as primary interface between the CAM program within Psychiatry and the MGH Office of Research Management/Finance for pre-award and post-award activity.
The Center for Addiction Medicine (CAM) is one of the major clinical research programs of the Department of Psychiatry at Massachusetts General Hospital. CAM delivers clinical evaluation, consultation and study-related clinical care in a multidisciplinary setting.
CAM offers outpatient treatment through several programs:
Addiction Recovery Management Service (ARMS)
ARMS is an outpatient clinic that specializes in care for youth ages 14-26 suffering from substance-related problems. The program gives families rapid access to information and provides support services for both youth patients and their families. ARMS also conducts outreach and care management for their patients.
West End Clinic for Addiction Treatment
The West End Clinic is an outpatient facility for those with alcohol and drug addictions, co-occurring mental health disorders and other types of addictive behaviors. The clinic offers both outpatient therapy and medication treatments in addition to other resources and support services.
Recovery Research Institute
The Recovery Research Institute offers resources to individuals in recovery and those seeking help with addiction, along with resources for family, friends and clinicians looking for ways to help a loved one.
CAM Clinical Trials
CAM also provides treatment through our clinical trials. The program conducts clinical trials related to many aspects of substance abuse disorders, including pharmacological and behavioral treatments of addiction, as well as the impact of addiction together with other conditions.
Collaborative Addiction Research Efforts
Gladys Pachas, MD, and Eden Evins, MD, MPH, conduct CAM research.
Drinking medicine before sleeping
The Center for Addiction Medicine (CAM) is involved in various collaborative efforts with clinics within Massachusetts General Hospital, Harvard Medical School, MIT and Tufts University, as well as community agencies in the Boston area.
Our research is always changing, but some of our recent research has included the following:
Real-time fMRI study: This is a cooperative effort between CAM and the Martinos Imaging Center at the McGovern Institute for Brain Research at MIT. The aim of this study is to develop real-time fMRI (functional magnetic resonance imaging) as an adjunct treatment for smoking cessation and other addictive disorders
Collaborations with North Suffolk Mental Health Association: These studies are testing different aspects of cognition, memory and attention in people with schizophrenia. Most significantly, recent findings have resulted in the recommendation of Bupropion for smoking cessation and relapse prevention in patients with schizophrenia
Evaluation of Sameem Associates' Adolescent Treatment Addiction Services program: This project is assessing the community-based agency's program to determine the intermediary and long-term outcomes of youth treated for substance use disorders and identify the mechanisms through which positive changes occur
Research Recovery Institute
Enhancing recovery through science
The Recovery Research Institute's website (RRI) is a non-profit research institute of Mass General's Department of Psychiatry and Harvard Medical School (501(c)(3)) located in Boston. In recognition of the increased public health and broader societal harms related to substance use disorders and the lack of emphasis on research pertaining to how individuals achieve remission and sustain long-term recovery, the Recovery Research institute was created in 2012 under the direction of John F. Kelly, PhD, with a goal of enhancing the public health impact of addiction recovery science through the summary, synthesis and distribution of scientific findings and the conduct of novel research investigation.
The Recovery Research Institute is home to the Recovery Research Review, a free electronic monthly publication containing contextualized summaries and syntheses of the latest research in addiction treatment and recovery. In addition, the RRI serves as a teaching and training center for promising researchers in addiction, funding two to three postdoctoral fellows each year.
In 2016, the Recovery Research Institute developed the MAPS software, groundbreaking in its ability to assist in the dynamic assessment of individuals with substance use disorders across clinical settings. The RRI worked also to expand its &ldquo, Addiction-ary &rdquo, to over 100 addiction-related terms and began a national effort to fight the stigmatization of addiction, leading the way in helping to align the language of addiction to be consistent with a broader public health approach to addressing substance use disorders.
In research for 2016, the RRI conducted the first study on the prevalence and pathways of addiction recovery using a nationally representative sample of 50,000 US adults, and the first ever study to characterize participation and benefits of online recovery support networks using the social network site InTheRooms.com.
John Kelly, PhD, and Eden Evins, MD, MPH, mentor CAM trainees.
Mass General is an integrated full-service primary, secondary and tertiary care hospital network with access to large numbers of diverse local patients, making it an ideal setting for clinical research in addiction. The hospital is home to thousands of basic and clinical scientists and collaboration is encouraged.
Each year up to three clinical fellows receive training in the Addiction Psychiatry Fellowship. Matriculants are board-eligible in addiction psychiatry.
The Center for Addiction Medicine (CAM) is strongly committed to training psychiatry residents, fellows, and psychology interns. CAM actively provides education for local and visiting medical students and residents who participate in twice weekly rounds, individual supervision, case presentations and three to five monthly didactic lectures. CAM&rsquo,s expert, multidisciplinary team translates scientific findings and applies evidence-based clinical strategies to create new models of care, leading to more favorable outcomes for this large but inadequately served population.